SRGL DD that will leave you seeing more than double. Surgilight is in the process of gaining FDA approval for a laser eye surgery that almost every person reading this post will probably have done to them some day. The procedure is called LAPR (Laser Presbyopia Reversal) and has 3 times the client base as lasik and effects people at a time in their life (40's & 50's) when most have enough money to actually pay for the surgery. . Presbyopia is a condition that causes you to get reading glasses and happens to almost every person in the world beginning around 40 years of age.
If you research presbyopia, you'll find that LAPR is without a doubt the safest, least intrusive and most effective procedure being tested. Surgilight has been conducting the surgery around the globe for approx 4 years now and have had amazing results. People who have not been able to read for 15+ years without the assistance of glasses are able to pick up a newspaper and read it without glasses almost immediately after surgery. Eyes receiving LAPR show almost no regression 3+ years post surgery, which is valuable data that should help speed along the Canadian and FDA approvals.
Now the two HUGE reasons that SRGL is worth buying right now:
1) The only way I found this via fax from the company. You won’t find it anywhere else for some reason. The stock would have and should run once word gets out about this.
February 2, 2005…Surgilight, Inc. (OTC Bulletin Board: SRGL) today announced it has received an additional clinical approval for the treatment, outside the US, of presbyopia for its already CE-approved OptiVisionTM. Presbyopia is a condition affecting nearly every individual over 40 in which there is a decline in unaided near-distance sight.
Known as CE 77964, 93/42/EEC, Annex IV, Section 4 Approval of the European Economic Community (EEC), this approval involves not only testing of the laser, but also a review of the clinical data by outside medical experts through the auspices of the British Standards Institute (BSI). The BSI clinical review states, in part, “The submission shows that reading vision has improved in the majority of their patients up to two years post-surgery and that they have not had any significant long-term complications.”
According to Surgilight Chairwoman and CEO Colette Cozean, Ph.D. this approval will allow the company to begin aggressively marketing the OptiVision for Laser Presbyopia Reversal (LAPR) throughout Europe, the Pacific Rim and around the world since many countries outside the U.S. recognize the CE standard. The company is awaiting FDA authorization to expand its U.S. clinical trials.
Dr. Cozean said that the European approval “represents a turning point for the Company as it opens doors for the introduction of LAPR to the majority of the world market.”
“Fortunately,” Dr. Cozean continued, “this approval is very timely inasmuch as the European Society for Cataract and Refractive Surgery will meet in Rome beginning February 4. Our European distributors plan to immediately expand their sales goals at this meeting.”
She added that the Company will now aggressively seek to license other leading European distributors in countries where it does not yet have distribution.
Surgilight, Inc. is a leader in the development and acquisition of new laser technologies for ophthalmic applications, including presbyopia reversal and treatment, cataract removal and treatment of glaucoma. The company holds 16 patents, with 23 patents pending.
2) This is even bigger news and once again, you won’t find under SRGL as a PR. It was released today by BIOLASE Technology, Inc. ( BLTI ).
--Feb 23, 2005 -- BIOLASE Technology, Inc. (NasdaqNM:BLTI - News), a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and related specialties, today announced the signing of a fully-paid license agreement related to patents owned or licensed by SurgiLight, Inc. in the field of Presbyopia, which is a phenomenon of natural aging that results in the loss of near-reading ability over the age of 40 years old. According to the Wall Street Journal article "Reading the Fine Print," published on February 14, 2005, 110 million Americans suffer from Presbyopia.
Subject to a due diligence period and satisfaction of certain terms and conditions, BIOLASE will acquire fully-paid license rights in the U.S. and International markets to patents owned or licensed by SurgiLight, Inc. in the field of Presbyopia and other patents related to the field of Ophthalmology. If certain terms and conditions are satisfactorily met, BIOLASE will pay an aggregate consideration of $2.0 million in cash, which will be paid in scheduled installments.
"We are pleased to acquire rights to this large market opportunity. We believe our technology offers distinct and strong advantages over currently known approaches to treating Presbyopia. While it is premature to discuss the specific commercial impact of this transaction to our forward business model, we are confident this agreement will open new commercial opportunities for BIOLASE's core technology," commented Robert E. Grant, President and CEO.
The agreement is expected to be completed in March 2005. All other terms and conditions of the transaction are confidential.
This funding should be all SRGL needs to reach FDA approval. At that point, it will become the most popular of all eye surgeries.
FYI, Surgilight’s procedure was recently featured on the “Today Show” 1/21/05, but did not mention the company behind the FDA trials although said it had “MUCH PROMISE”.
HomerRomer
